Cohance Lifesciences (BOM:543064) Other Current Payables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543064 Cohance Lifesciences Ltd BOM:543064
88 GF Score
Price ₹462.60
GF Value ₹644.12
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Cohance Lifesciences Other Current Payables?

Cohance Lifesciences BOM:543064 -2.72% 88 Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:543064 with a GF Score™ of 88/100 and a GF Value™ of ₹644.12 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Cohance Lifesciences's Other Current Payables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Cohance Lifesciences's quarterly Other Current Payables declined from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹-0 Mil) but then increased from Mar. 2026 (₹-0 Mil) to Jun. 2026 (₹0 Mil).

Cohance Lifesciences's annual Other Current Payables increased from Mar. 2024 (₹88 Mil) to Mar. 2025 (₹625 Mil) but then declined from Mar. 2025 (₹625 Mil) to Mar. 2026 (₹-0 Mil).

Cohance Lifesciences Other Current Payables Related Terms

Cohance Lifesciences Other Current Payables Historical Data

* Premium members only.

The historical data trend for Cohance Lifesciences's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Other Current Payables Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial 21.27 163.93 88.40 624.60 -0.00

Cohance Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 0.00
BOM:543064
88GF Score
Cohance Lifesciences Ltd BOM:543064
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cohance Lifesciences Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Cohance Lifesciences (BOM:543064) has a Other Current Payables of ₹0 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cohance Lifesciences and its competitors.
Is Cohance Lifesciences' Other Current Payables too high?
Cohance Lifesciences' current Other Current Payables is ₹0 Mil. Overall, Cohance Lifesciences has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Other Current Payables compare to ZTS?
Cohance Lifesciences' Other Current Payables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Cohance Lifesciences and its competitors. Cohance Lifesciences's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹644.12, compared to a current price of ₹462.60 — trading 28.2% below its estimated fair value. The current Other Current Payables is ₹0 Mil. Cohance Lifesciences' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹462.60 is trading 28.2% below its estimated GF Value™ of ₹644.12. GuruFocus considers Cohance Lifesciences to be Modestly Undervalued.

Key valuation signals for BOM:543064:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹644.12 vs. price of ₹462.60 (28.2% below fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges COHANCE:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
88GF Score

Get the complete analysis for BOM:543064

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹462.60
Price
₹644.12
GF Value